



**5th INTERNATIONAL
FORUM ON MOOD
AND ANXIETY DISORDERS**

**Scientific
Programme**



WEDNESDAY, November 9, 2005

16.00 – 18.00

S01 - SUICIDE OVERVIEW

Chair: L. Pezawas (Austria) - J. Zohar (Israel)

S0101 - Predictors and prevention of suicide

J. Angst (Switzerland)

S0102 - Suicide and antidepressants

J. Sinclair (United Kingdom)

S0103 - Toxicity of antidepressants in overdose

R. Frey (Austria)

S0104 - Suicidality and mortality in PTSD

J. Zohar (Israel)

18.00 – 20.00

**S02 - IS THERE A TREATMENT
FOR RECURRENT BRIEF DEPRESSION?**

Chair: J. Angst (Switzerland) - R. Frey (Austria)

S0201 - Diagnostic issues

H. Løvdahl (Norway)

S0202 - Epidemiology

J. Angst (Switzerland)

S0203 - Genetic influence on mood circuitries

L. Pezawas (Austria)

S0204 - Treatment

S. Kasper (Austria)

20.00 – 20.30

Opening Reception – Welcome Cocktail



THURSDAY, November 10, 2005

08.30 - 10.30 _____

S03 - ARE THERE SUPERIOR ANTIDEPRESSANTS?

Chair: P. Delgado (USA) - S. Montgomery (United Kingdom)

S0301 - Focus on Escitalopram

R. Nil (Switzerland)

S0302 - Focus on Venlafaxine

R. Entsuah (USA)

S0303 - Focus on Milnacipran

F. Denis (France)

S0304 - Focus on Mirtazapine

A. Szegedi (The Netherlands)

10.30 - 10.45 *Coffee Break & Poster Session*

10.45 - 12.45 _____

S04 - NEW ANTIDEPRESSANTS

HOW DO THEY WORK AND HOW EFFECTIVE ARE THEY?

Chair: S. Montgomery (United Kingdom)

S0401 - What can we learn from pre-clinical studies of antidepressants?

P. Blier (Canada)

S0402 - Escitalopram vs. the SSRI citalopram - results from a randomised head-to-head study

N. Moore (France)

S0403 - Are antidepressants equally effective in severe depression?

S. Montgomery (United Kingdom)

S0404 - Time to antidepressive effect - which antidepressant works best?

S. Kasper (Austria)

Sponsored by an unrestricted educational grant of H. LUNDBECK A/S

12.45 - 13.45 _____

Lunch



13.45 – 15.45

S05 - SEXUALITY

Chair: **D. S. Baldwin** (*United Kingdom*) - **M. D. Waldinger** (*The Netherlands*)

- S0501** - Sexual dysfunction with antidepressants
D. S. Baldwin (*United Kingdom*)
- S0502** - Is there a way to improve sexual dysfunction in depression?
A. Tölk (*Austria*)
- S0503** - Differential impairment of sexual dysfunction with antidepressants
A. L. Montejo Gonzalez (*Spain*)
- S0504** - Drug treatment of premature ejaculation
M. D. Waldinger (*The Netherlands*)

15.45 – 16.00 *Coffee Break & Poster Session*

16.00 – 18.00

S06 - SNRIs ALL FOR ONE AND ONE FOR ALL?

Chair: **S. Kasper** (*Austria*)

- S0601** - SNRIs Fruit of a logical evolution of antidepressant action
S. Montgomery (*United Kingdom*)
- S0602** - SNRIs a new generation of treatment for anxiety disorders
D. S. Baldwin (*United Kingdom*)
- S0603** - SNRIs new hope in the treatment of chronic pain
P. Delgado (*USA*)
- S0604** - SNRIs Vive la différence
P. Blier (*Canada*)

Sponsored by an unrestricted educational grant of **PIERRE FABRE MEDICAMENT**

18.00 – 20.00

S07 - TREATMENT UPDATE IN GAD

Chair: **M. Lader** (*United Kingdom*), **M. de Zwaan** (*Germany*)

- S0701** - Escitalopram in the anxiety disorders
M. Lader (*United Kingdom*)
- S0702** - Pregabalin: a new pharmacological tool for the treatment of GAD
C. Altamura (*Italy*)
- S0703** - A critical review of CBT in GAD
M. de Zwaan (*Germany*)
- S0704** - Is there an algorithm for treatment of GAD?
B. Bandelow (*Germany*)



FRIDAY, November 11, 2005

08.30 - 10.30 _____

S08 - ANTIDEPRESSANTS AND PAIN

Chair: C. Altamura (Italy), M. Briley (France)

S0801 - Fibromyalgia and antidepressants

M. Briley (France)

S0802 - Duloxetine and the control of pain

M. Detke (USA)

S0803 - SSRIs and painful symptoms in depression

H. Agren (Sweden)

S0804 - Pregabalin and the treatment of neuropathic pain

T. K. Murphy (USA)

10.30 - 10.45 *Coffee Break & Poster Session*

10.45 - 12.45 _____

S09 - DIAGNOSIS AND TREATMENT OF DEMENTIA

Chair: C. K. Broich (Germany), Sampaio (Portugal)

S0901 - Brain-imaging diagnostic and outcome markers in Alzheimer's disease - ready as surrogate parameters?

K. Broich (Germany)

S0902 - Designs for demonstrating efficacy in Age Associated Memory Impairment (AAMI)

G. Dunbar (USA)

S0903 - Obstacles in demonstrating efficacy in Minimal Cognitive Impairment (MCI)

C. Sampaio (Portugal)

S0904 - New strategies in the treatment of BPSD in dementia

D. Kunz (Germany)

12.45 - 13.45 _____

Lunch



13.45 – 15.45

S10 - NEW INSIGHTS IN TREATMENT RESISTANT DEPRESSION (TRD)

Chair: **E. Seifritz (Switzerland)**, **D. Souery (Belgium)**

S1001 - Diagnosis and definition
Y. Lecrubier (France)

S1002 - European program on TRD
D. Souery (Belgium)

S1003 - Molecular basis of TRD
H. Aschauer (Austria)

S1004 - Brain mechanisms of TRD
E. Seifritz (Switzerland)

15.45 – 16.00 *Coffee Break & Poster Session*

16.00 – 18.00

S11 - LONG-TERM TREATMENT OF BIPOLAR DISORDER

Chair: **J. Cookson (United Kingdom)**, **T. Schlöpfer (Germany)**

S1101 - Are atypicals mood stabilizers?
H. Grunze (Germany)

S1102 - Antidepressants in bipolar depression
J. Cookson (United Kingdom)

S1103 - Brain stimulation for depression
T. Schlöpfer (Germany)

S1104 - Suicidality
A. Erfurth (Austria)

18.00 – 18.15

CLOSURE



- P01.** MCMHI personality profile of depressive patients. **A.E. Afkham**^{1,2,3}, **M. Salehi**^{1,2,4}, **B. Daneshamouz**^{1,2,4} (Iran University of Medical Sciences, ²Tehran Institute of Psychiatry, ³Rasoul Akram Hospital, ⁴Iran Psychiatric Center, Iran).
- P02.** Escitalopram for relapse prevention in generalised anxiety disorder. **C. Allgulander**¹, **A. Huusom**², **I. Florea**² (Karolinska Institutet, Sweden, Neurotec Department, Section of Psychiatry, ²H. Lundbeck A/S, Denmark).
- P03.** Is the nutritional pattern of school children with attention deficit/hyperactivity disorder different from normal subjects? **R. Amani**¹, **N. Khaje-Mougahi**² (Dept. of Nutrition, Ahvaz Jundi Shapour University of Med. Sciences, ²Golestan Hospital, Iran).
- P04.** A randomised trial of escitalopram and paroxetine in the treatment of GAD. **D.S. Baldwin**¹, **E. Mæhlum**², **A. Huusom**² (Clinical Neuroscience Division, University of Southampton, U.K., ²H. Lundbeck A/S).
- P05.** Sertraline in the treatment of patients with depression and psoriasis. **L.M. Bardenshteyn**¹, **Y.I. Voronina**² (Moscow State University of Medicine and Dentistry, Department of Psychiatry and Narcology, ²Moscow State University of Medicine and Dentistry, Department of Dermatology and Venereology, Moscow, Russia).
- P06.** Results of a Spanish nationwide cross-sectional study on major depression IV: relationship between somatic symptoms, quality of life and resource utilization. **L. Caballero**¹, **E. Aragonés**², **J. García-Campayo**³, **F. Rodríguez-Artalejo**⁴, **J. L. Ayuso-Mateos**⁵, **M. J. Polavieja**⁶, **E. Gómez-Utrero**⁶, **I. Romera**⁶, **I. Gilaberte**⁶ (Puerta de Hierro Hospital, ²Constantí primary health care center, ³Miguel Servet Hospital, ⁴Universidad Autónoma de Madrid, ⁵La Princesa hospital, ⁶Clinical research department, Lilly Spain, Spain).
- P07.** Results of a Spanish nationwide cross-sectional study on major depression in primary care III: relationship between somatic symptoms and severity of depression. **L. Caballero**¹, **E. Aragonés**², **J. García-Campayo**³, **F. Rodríguez-Artalejo**⁴, **J. L. Ayuso-Mateos**⁵, **M.J. Polavieja**⁶, **E Gómez-Utero**⁶, **I. Romera**⁶, **I. Gilaberte**⁶ (Puerta de Hierro Hospital, ²Constantí primary health Care Center, ³Miguel Servet Hospital, ⁴Universidad Autónoma de Madrid, ⁵La Princesa Hospital, ⁶Clinical research department, Lilly Spain, Spain).
- P08.** Results of a Spanish nationwide cross-sectional study on major depression in primary care II: prevalence and factors related to somatization disorder. **L. Caballero**¹, **E. Aragonés**², **J. García-Campayo**³, **F. Rodríguez-Artalejo**⁴, **J. L. Ayuso-Mateos**⁵, **M.J. Polavieja**⁶, **E. Gómez-Utrero**⁶, **I. Romera**⁶, **I. Gilaberte**⁶ (Puerta de Hierro Hospital, ²Constantí primary health care center, ³Miguel Servet Hospital, ⁴Universidad Autónoma de Madrid, ⁵La Princesa Hospital, ⁶Clinical research department, Lilly Spain, Spain).
- P09.** Results of a Spanish nationwide cross-sectional study on major depression in primary care I: prevalence and characteristics of somatic symptoms. **L. Caballero**¹, **E. Aragonés**², **J. García-Campayo**³, **F. Rodríguez-Artalejo**⁴, **J. L. Ayuso-Mateos**⁵, **M.J. Polavieja**⁶, **E. Gómez-Utrero**⁶, **I. Romera**⁶, **I. Gilaberte**⁶ (Puerta de Hierro Hospital, ²Constantí primary health care center, ³Miguel Servet Hospital, ⁴Universidad Autónoma de Madrid, ⁵La Princesa Hospital, ⁶Clinical research department, Lilly Spain, Spain).
- P10.** Pilot study of clonazepam and milnacipran in the treatment of patients with panic disorder with comorbid major depression. **A.H. Cia**¹, **J.A. Brizuela**¹, **E. Cascardo**¹, **M.F. Varela**¹ (Clinica Moravia, Buenos Aires, Argentina)



POSTERS

P11. Effectiveness and tolerability of amisulpride in bipolar disorders, treatment of bipolar mania: results of a 24-week open study. **¹C. Cimmino**, **²G. Foggia**, **³I. Celentano**, **⁴G. Barra**, **⁵M. Romano**, **⁶A. Rocco**, **⁷T. Cante**, **⁸E. Mauro**, **⁹C. Ciliberti** (Psychiatry Emergency Hospital, "San Giovanni di Dio", Frattaminore, Napoli, Italy).

P12. The treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. **J. Cookson¹**, **I. Gilaberte²**, **D. Desai³**, **D. Kajdasz³** (¹Royal London Hospital, ²Lilly S.A., ³Lilly Research Laboratories, UK)

P13. Why is self-help neglected in the treatment of emotional disorders? A meta-analysis. **P.C.A.M. den Boer¹**, **D. Wiersma¹**, **R.J. Van den Bosch¹** (¹University Medical Center Groningen, Groningen, The Netherlands)

P14. Cognitive self-therapy in the treatment of chronic and remittent emotional disorders. A multi-centre randomised controlled trial. **P.C.A.M. den Boer¹**, **D. Wiersma¹**, **I. den Vaarwerk¹**, **M.M. Span¹**, **A.D. Stant¹**, **R.J. Van den Bosch¹** (¹University Medical Center Groningen, Groningen, The Netherlands)

P15. Paraprofessionals for anxiety and depressive disorders. A meta-analysis. **P.C.A.M. den Boer¹**, **D. Wiersma¹**, **S. Russo¹**, **R.J. Van den Bosch¹** (¹University Medical Center, Groningen, The Netherlands).

P16. Modafinil as an adjunct treatment to sleep deprivation in depression. **C. Even¹**, **J. Thuile¹**, **J.D. Guelfi¹**, **P. Bourgin²** (¹Clinique des maladies mentales et de l'encephale, Centre Hospitalier Sainte-Anne, Université Rene Descartes Paris-V, France, ²Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Center for Narcolepsy Research, USA).

P17. Treatment of anxious vs. non-anxious depression: a posthoc analysis of an open-label study of duloxetine. **M. Fava¹**, **J. Martinez^{2,3}**, **L. Marangell^{2,3}**, **J. Greist⁴**, **E. Brown⁵**, **I. Chen⁵**, **M. Detke⁵**, **M. Wohlreich⁵**. (¹Massachusetts General Hospital, ²Baylor College of Medicine, ³Dept. of Veteran Affairs, ⁴Healthcare Technology Systems, ⁵Eli Lilly and Company, USA).

P18. Posttraumatic stress disorder and perception of health after 11m attacks in Madrid. **D. Fraguas¹**, **S. Teran¹**, **J. Conejalgalindo¹**, **O. Medina¹**, **E Sainz-Corton¹**, **C Arango¹** (¹Hospital Gregorio Marañón, Madrid, Spain).

P19. Winter seasonal affective disorder and night eating syndrome
S. Friedman¹, **C. Even¹**, **J. Thuile¹**, **C. Yacoub¹**, **N El-Haddad¹**, **J.D. Guelfi¹** (¹Cmme, Centre Hospitalier Sainte-Anne, Université René Descartes Paris V, France).

P20. Novel hypothesis for the cause of panic disorder via the neuroepithelial bodies in the lung. **K. Fukuda¹** (¹Souka-Shinryounaika, Souka City, Japan).

P21. Psychological factors involved in the chronification of pain. **R. García Nieto¹**, **J.A. Gómez Terrados¹** (¹Rio Hortega Pain Unit, Spain).

P22. Effectiveness of psychoeducation in the treatment of bipolar disorder. **R. Garcia Nieto¹**, **F. de la Torre Brasas¹**, **B. Cantero Fernández¹** (¹Delicias Mental Health Center, Spain).

P23. Escitalopram for relapse prevention in older patients with depression. **P. Gorwood¹**, **O. Lemming²**, **E. Weiller²**, **C. Katona³** (¹Hôpital Louis Mourier, France, ²H. Lundbeck A/S, ³Kent Institute of Medicine & Health Sciences, University of Kent, UK).



P24. Neuropsychological correlations of symptom dimensions of obsessive-compulsive disorder. **T.H. Ha¹, J.S. Kwon¹, K.S. Ha¹** (¹Department of Psychiatry, Seoul National University College of Medicine, Korea).

P25. Analysis of relation between time management behaviors and occupational stress of medical surgical wards. **H. Hashemizadeh¹, S. KH Hoviat Thalab²** (¹Ghoochan Azad Islamic University, ²Shaheed Beheshti Medical University, Iran).

P26. Onset of action of escitalopram: results of a pooled analysis. **S. Kasper¹, C. Spadone², P. Verpillat³, J. Angst⁴** (¹Department of General Psychiatry, Medical University of Vienna, Austria ²Hôpital Saint-Louis, ³H. Lundbeck A/S, France, ⁴Zurich University Psychiatric Hospital, Switzerland).

P27. A pooled analysis of selective serotonin reuptake inhibitors (SSRIs) and venlafaxine. **S.H. Kennedy¹, H.F. Andersen², R. Nil², R.W. Lam³** (¹University Health Network, University of Toronto, Canada, ²H. Lundbeck A/S, Switzerland, ³University of British Columbia, Canada).

P28. Frontal dysfunction underlies depressive syndrome in Alzheimer's disease: a fdg-PET study. **D.Y. Lee^{1,2}, I.H. Choo¹, J.H. Hoo³, K.W. Kim⁴, J.C. Youn⁵, D.S. Lee⁶, E.J. Kang⁷, J.S. Lee⁶, W.J. Kang⁶, J.I. Woo^{1,8}** (¹Department of Neuropsychiatry and Clinical Research Institute, Seoul National University Hospital, ²Interdisciplinary Program of Cognitive Science, Seoul National University, ³Department of Psychiatry, Pundang Jesaeng Hospital, Daejin Medical Center, Seongnam, ⁴Department of Neuropsychiatry, Seoul National University Bundang hospital, Seongnam, ⁵Department of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Yongin, ⁶Department of nuclear medicine, Seoul National University Hospital, ⁷Department of Psychology, College of Social Science, Kangwon National University, ⁸Neuroscience Research Institute of the Medical

Research Center, Seoul National University, Korea).

P29. Seasonality associated with the serotonin 2A receptor polymorphism. **H.J. Lee¹, S.M. Sung¹, L. Kim¹** (¹Department of Psychiatry, Korea University College of Medicine, Korea).

P30. Interpersonal group psychotherapy in bipolar outpatients. **M. Martin¹, A. Fernandez-Cuevas¹** (¹Hospital Universitario Gregorio Marañon, Spain).

P31. Anxiety and mood disorders in children with learning disabilities. **A. Michopoulou¹, V. Goula¹, S.M. Papatheodorou¹, G. Stefanou¹, D. Giannios¹, A. Nikolaou¹, R. Athanasiadou¹, A. Iliadou¹, K. Voikli¹, B. Belessioti¹** (¹Penteli's Children Hospital, Palea Penteli, Greece).

P32. Escitalopram and suicidality in depression in adults. **A.G. Pedersen¹, K.F. Overø¹** (¹H. Lundbeck A/S, Denmark).

P33. Discontinuation-emergent symptoms of duloxetine treatment in patients with major depressive disorder. **D. Perahia^{1,2}, D. Kajdasz³, D. Desai³, P. Haddad⁴** (¹Lilly Research Centre, USA, ²The Gordon Hospital, ³Lilly Research Laboratories, ⁴University of Manchester, UK).

P34. Seasonal birth distribution in healthy siblings of melancholic and atypical SAD patients. **E. Pjrek¹, D. Winkler¹, A. Konstantinidis¹, J. Stastny¹, N. Prashak-Rieder², M. Willeit², S. Kasper¹** (¹Department of General Psychiatry, Medical University of Vienna, Austria, ²Centre of Addiction and Mental Health, Toronto, Canada).

P35. Compliance with-weekly fluoxetine vs daily-fluoxetine and other selective serotonin reuptake inhibitors after the maintenance therapy in major depressive disorder. **I. Romera¹, S. López², J. Arbesu³, V. Gasull⁴, J. Garraleta⁵, I. Gilaberte¹** (¹Clinical Research Department,



POSTERS

Lilly Spain, ²Primary Health Care Center Paseo Extremadura, ³Primary Health Care Center Sama de Langreo, ⁴Primary Health Care Center Aldaia, ⁵Primary Health Care Center Espartero, Spain).

P36. Vulnerability to psychosis increases the risk of depression. **R. K. R. Salokangas**^{1,2,3}, **S. Luutonen**^{1,2}, **M. Nieminen**¹, **J. Huttunen**¹, **H. Karlsson**⁴ (¹Department of Psychiatry, University of Turku, ²Psychiatric Clinic, Turku University Central Hospital, ³Turku Psychiatric Clinic, Turku Mental Health Centre, ⁴Department of Psychiatry, University of Helsinki, Finland).

P37. PET neuroimaging of [¹¹C]mirtazapine antidepressant sites in humans and [¹¹C]mirtazapine enantiomers in pigs. **K. Smith**^{1,3}, **D. F. Jako**^{1,2}, **S. Marthinsen**¹, **D. Bender**¹, **S.B. Hansen**¹, **B. Smith**², **F. Hermansen**¹, **R. Rosenberg**², **P. Cumming**¹ (¹PET Center, Aarhus, University Hospital, Aarhus C, ²Center for Basic Psychiatric Research, Psychiatric Hospital, Risskov, Denmark, ³Hungarian Academy of Sciences, Research Group of Technical Analytical Chemistry, Budapest, Hungary).

P38. The measurement of anxiety in depression. **L. Stefanovic**¹, **M. Munjiza**¹ (¹Institute for Mental Health, Belgrade, Serbia).

P39. Escitalopram and GAD: efficacy across different subgroups and outcomes. **D. Stein**¹, **R. Nil**², **H.F. Andersen**², **W.K. Goodman**³ (¹MRC Unit on Anxiety Disorders, University of Stellenbosch, South Africa, ²H. Lundbeck A/S, Switzerland, ³University of Florida, USA)

P40. Onset of action of quetiapine monotherapy in bipolar mania. **E. Vieta**¹, **B. Paulsson**², **J. Mullen**³, **M. Brecher**³ (¹Hospital clinic, Idibaps, University of Barcelona, ²Astrazeneca, ³Astrazeneca).

P41. Psychiatric comorbidity of l- and d/l-methadone maintained patients - prevalence, additional intake of drugs, gender, and addictive substance-related behaviour. **D. Wedekind**¹, **S. Jacobs**², **I. Karg**², **C. Lüdecke**³, **U. Schneider**⁴, **K. Cimander**⁵, **E. Rhüther**¹, **W. Poser**¹, **U. Havemann-Reinecke**¹ (¹Univ. of Goettingen, Dept of Psychiatry, ²Univ. of Goettingen, Dept of Psychology, ³Niedersächsisches landeskrankenhaus Goettingen, ⁴Medizinische Hochschule Hannover, ⁵Praxis für Drogenkranke, Hannover, Germany).

P42. Hypersomnia in atypical seasonal depression – a comparison between objective measurements and subjective reports. **D. Winkler**¹, **E. Pjrek**¹, **J. Stastny**¹, **A. Konstantinidis**¹, **N. Praszak-Rieder**², **M. Willeit**², **S.Kasper**¹, (¹Department of General Psychiatry, Medical University of Vienna, Austria, ²Centre of Addiction and Mental Health, Toronto, Canada).